Admont - Admont is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Admont blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Admont is marketed in United States and many other countries by Merck & Co. with the brand name SingulairÂ®. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla.|
Indication: For the treatment of asthma
Admont, like zafirlukast, is a leukotriene receptor antagonist used as an alternative to anti-inflammatory medications in the management and chronic treatment of asthma and exercise-induced bronchospasm (EIB). Unlike zafirlukast, Admont does not inhibit CYP2C9 or CYP3A4 and is, therefore, not expected to affect the hepatic clearance of drugs metabolized by these enzymes.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products:
Admont available forms, composition, doses:
- Tablets; Oral; Montelukast 10 mg
Admont destination | category:
- Antiasthmatic and COPD preparations
- Antihistamines and antiallergics
- Leukotriene modifiers
Indications and usages, anatomical therapeutic chemical and diseases classification codes:
Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers:
There is no reviews yet. Be the first to write one!